Analysis of Wearable Injector Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Worldwide revenue from wearable injector sales is estimated to reach US$ 8.35 billion in 2024. The global wearable injector market size has been analyzed to climb to a value of US$ 29.64 billion by the end of 2034, expanding at a remarkable CAGR of 13.5% over the next ten years (2024 to 2034).
A wearable injector is a type of medical device used to administer drugs or other medications under the skin under strict control. The device is discreetly and conveniently worn on the body as a small pump or patch for drug administration.
On-body injectors in wearable injectors provide long-lasting therapeutic effects, which improve patient compliance and treatment efficacy. By making the administration process simpler, wearable injectors with a large volume have been shown to increase medication adherence. Many dosing options are available with the sophisticated wearable injection device, including basal, bolus, and continuous delivery.
Key Market Growth Drivers
| Report Attribute | Detail |
|---|---|
| Wearable Injector Market Size (2024E) | US$ 8.35 Billion |
| Forecasted Market Value (2034F) | US$ 29.64 Billion |
| Global Market Growth Rate (2024 to 2034) | 13.5% CAGR |
| East Asia Market Share (2024E) | 14.1% |
| North America Market Share (2024E) | 37.3% |
| Sales of Body-Worn Patch Injectors (2024E) | US$ 7.12 Billion |
| Key Companies Profiled | West Pharmaceutical Services, Inc.; Bespak; Amgen Inc.; Insulet Corporation; Valeritas Inc.; Dexcom, Inc.; Ypsomed Group; Tandem Diabetes Care, Inc.; Becton, Dickinson and Company; MannKind Corporation. |
“Patient-Centricity and Greater Focus on Human Factors in Drug Delivery Design”
Wearable injection systems are drug-delivery devices that attach to the body and automatically deliver predetermined doses to the patient at optimal times. Wearable injection systems are the logical progression of chronic disease management in a society where everything must happen instantly. The notion of patient-centricity and a heightened emphasis on human factors in drug-delivery design are key wearable injector market trends.
Development of delivery systems capable of handling high-viscosity solutions has been made necessary by the trend toward the use of biologics in pharmaceutical development. These circumstances have led to the emergence of wearable injection systems.
“High Cost of Wearable Injectable Drugs and Restricting Availability”
As technology advances, various drug delivery systems are being developed to make it easier for patients to receive medication efficiently and conveniently. Wearable injectable medications are significantly more expensive than auto-injectors and other injectors, such as pens. When it comes to administering insulin, there are a lot of options available besides less costly delivery systems such as standard prefilled syringes and insulin pens.
The public health system does not promote the use of wearable injectable devices. This is a result of the device's high cost, the paucity of reimbursement choices, and low patient awareness of the technology. The device's restricted availability adds yet another challenge for market players.
Growth of the market in North America is driven by fueled by the rising interest in and adoption of such devices in the region. As wearable injectors are more expensive than other devices, the availability of reimbursement is projected to play an important role in fueling market growth. Government initiatives aimed at promoting the use of wearable injectors, rising healthcare costs, and an aging population are also contributing to the expansion of the wearable injector market size in the region.
“Reimbursements for Therapeutic Drug Delivery Making Wearable Injectors Accessible to More Patients”
| Attribute | United States |
|---|---|
| Market Value (2024E) | US$ 2.77 Billion |
| Growth Rate (2024 to 2034) | 9.7% CAGR |
| Projected Value (2034F) | US$ 6.99 Billion |
The United States is estimated to hold 89.1% of the wearable injector market share in North America in 2024. Use of wearable injectors is increasing in the United States at a remarkable pace due to a well-established healthcare system and a rise in the prevalence of chronic diseases related to lifestyle choices. There is growing demand in the country due to the local presence of major market players in the United States, such as Becton, Dickinson and Company, and Johnson & Johnson Services, Inc. Reimbursements for therapeutic drug delivery are also driving market growth.
“C150 Category Simplifying Reimbursement Process and Improving Diabetes Care”
| Attribute | Japan |
|---|---|
| Market Value (2024E) | US$ 400 Million |
| Growth Rate (2024 to 2034) | 14.9% CAGR |
| Projected Value (2034F) | US$ 1.6 Billion |
Japan is expected to account for 34% share of the East Asia market in 2024. Japan's medical insurance system has added a new category known as "C150." It includes all people with diabetes who meet the requirements to be eligible for financial aid in Japan for the purchase of the Dexcom G6 continuous glucose monitor (CGM). Everyone who injects themselves with insulin at least once a day is classified as falling into Japan's new C150 category.
Everyone who meets the requirements is covered, regardless of the type of diabetes they have. Hospitals are no longer required to apply for eligibility under the Japanese medical insurance program. The new category allows reimbursement to be received by all hospitals.
Wearable infusion pumps or off-body injectors are small, lightweight devices that patients can wear on their belts with an attached cannula to the skin. They are estimated to occupy 14.7% market share in 2024. These enable patients to move freely throughout the course of treatment, making them perfect for those who need continuous or sporadic infusions over an extended period. With a tube connecting the pump to the infusion set that is positioned in the subcutaneous fatty tissue, the majority of insulin pumps are worn on belts.
“Body-Worn Injectors Effectively Handling Increasing Dosage Volumes and Viscosities”
| Attribute | Body-Worn Patch Injector |
|---|---|
| Segment Value (2024E) | US$ 7.12 Billion |
| Growth Rate (2024 to 2034) | 13.7% CAGR |
| Projected Value (2034F) | US$ 25.59 Billion |
Body-worn patch injectors are set to hold a significant market share of 85.3% in 2024. Subcutaneous injections of biological and pharmaceutical therapies are carried out through the use of patch injectors worn on the body. Using an adhesive, the device is affixed to the patient's skin directly. Depending on the dimensions of the device, this adhesive surface can stretch to the size of a mobile phone's face.
These wearable injectors have the potential to successfully address the challenge of administering subcutaneous injections in non-clinical settings with increasing dosage volumes and viscosities. Body-worn wearable injectors effectively address the challenge of administering subcutaneous injections in non-clinical settings with increasing dosage volumes and viscosities.
“Convenience in Obtaining and Using Diverse Wearable Injectors”
| Attribute | Retail Pharmacies |
|---|---|
| Segment Value (2024E) | US$ 2.85 Billion |
| Growth Rate (2024 to 2034) | 13.4% CAGR |
| Projected Value (2034F) | US$ 10.17 Billion |
Retail pharmacies are poised to hold a market share of 34.7% in 2024. The retail pharmacies segment maintains a high market share due to the growing number of patients using ultra-large volumes of wearable injectors for various drug deliveries. It is simple to obtain and use a variety of wearable injectors because they are sold and used in retail pharmacies and drug stores. Retail pharmacies occupy a significant market share worldwide due to improved product accessibility and the ensuing increase in product adoption.
Key players in the wearable injector market have been working together with industry and non-industry participants mainly for product and technology integration. In collaboration with manufacturers of delivery devices, drug developers are assessing innovative drug delivery methods for their drug candidates during preclinical phases.
Fact.MR provides detailed information about the price points of key providers of wearable injectors positioned across the world, sales growth, production capacity, and speculative technological expansion in this new market report.
How big is the wearable injector market in 2024?
The global market for wearable injectors is expected to be valued at US$ 8.35 billion in 2024.
What are the sales projections for wearable injectors for 2034?
The market is forecasted to expand at 13.5% CAGR and reach US$ 29.64 billion by the end of 2034.
Which country has a significant market for wearable injectors?
Revenue from wearable injector sales in the United States is projected to reach US$ 2.77 billion in 2024.
What are the projections for the market in China?
China is estimated to reach a market value of US$ 572 million in 2024.
Which distribution channel accounts for higher sales of wearable injectors?
Market revenue from hospital pharmacies is estimated to reach US$ 2.85 billion in 2024.
What is the market share of Japan in East Asia?
Japan accounts for a market share of 34% in East Asia in 2024.
Who are the leaders in the business of wearable injectors?
Tandem Diabetes Care, Inc., Becton Dickinson, and Company, and MannKind Corporation are some of the key players in the market.
Wearable Injector Market